Zacks Investment Research | Aug 07, 2019 10:54PM ET
Celldex Therapeutics, Inc. (NASDAQ:CLDX) incurred adjusted second-quarter 2019 loss (excluding gain on fair value re-measurement of contingent consideration) of 92 cents per share, narrower than the Zacks Consensus Estimate of a loss of $1.17 and the year-ago loss of $2.43. However, including the fair value re-measurement item, the reported loss was 84 cents narrower than loss of $1.67 in the year-ago period
However, total revenues in the quarter declined 75% year over year to $0.7 million and missed the Zacks Consensus Estimate of $1.26 million. The year-over-year decline was due to decrease in revenues from the collaboration agreement with Bristol-Myers (NYSE:BMY) and contract agreement with the International AIDS Vaccine Initiative.
Celldex share price performance has been disappointing so far this year. The stock has declined 27.2% compared with the industry ’s 2.9% decrease.
Costs Decline
Research and development expenses were down 52.8% year over year to $10.1 million during the quarter mainly due to lower personnel costs and decline in clinical study and contract manufacturing related expenses. General and administrative expenses were $3.9 million, down 30.4% year over year mainly attributable to lower personnel and marketing expense.
As of Jun 30, 2019, Celldex had cash, cash equivalents and marketable securities of $81.3 million compared with $85.1 million as of Mar 31, 2019. The biotech company’s weakened cash position was due to higher operating expense, partially offset by net proceeds raised from sales of its common stock under a contract with Cantor.
2019 Outlook
Celldex believes that its cash position as of the end of June plus anticipated net proceeds from future sales of its common stock under the agreement with Cantor will be adequate to fund working capital requirements as well as planned operations through 2020.
Pipeline Focus
Celldex is focused on development of CDX-1140 and CDX-3379. Although the candidates are in early to mid-stage studies, the company is progressing well with the studies.
In the earnings release, the company announced that it has completed enrollment in the monotherapy arm of the phase I study evaluating CDX-1140 in patients with recurrent, locally advanced or metastatic solid tumors and B cell lymphomas. Meanwhile, enrollment in another arm of the study evaluating a combination of CDX-1140 and CDX-301 is on track. The company has completed dose limiting toxicity for eight monotherapy doses and three combination doses. The fourth combination dose is under review. Detailed data will be presented at a medical meeting by year end. The company may evaluate CDX-1140 in combination with PD-1 or PD-L1 inhibitors, chemotherapy, radiation therapy and Celldex’s monoclonal antibody candidate, varlilumab, going forward. Interim data announced in April showed that CDX-1140 was safe.
Currently, enrollment is underway in a phase II study evaluating CDX-3379 in combination with Eli Lilly’s (NYSE:LLY) Erbitux for the treatment of advanced head and neck squamous cell cancer. Interim data announced in June supported further evaluation of CDX-3379. Based on the data, Celldex expanded the patient population to focus on the development of CDX-3379 in biomarker selected patient population.
The company is planning to file an investigational new drug application by the end of the year to initiate a phase Ia study to evaluate pre-clinical monoclonal antibody candidate, CDX-0159, in inflammatory diseases.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.